
ASCO 2025: Real-World Outcomes of Frontline ICI Therapy in BRAF-Mutated Melanoma in the Community Setting
The emergence of immune checkpoint inhibitors (ICIs) has significantly improved outcomes for patients with advanced melanoma, including those with BRAF mutations who are at heightened risk for developing melanoma brain metastases (MBM). Yet, real-world …